Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently reported encouraging data from its pivotal bioequivalence study for pitolisant gastro-resistant (GR), marking a major milestone as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback